Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CH505TF gp120 + GLA-SE in HIV-exposed Uninfected Infants
NCT04607408Phase 1Completed
- Sponsor
- HIV Vaccine Trials Network
- Start
- Nov 2020
- Primary completion
- Jul 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised trial of CH505TF gp120 in human immunodeficiency virus infection (HIV) (8 arms), sponsored by HIV Vaccine Trials Network. Primary endpoints: WHO Anthropometric Measure of Weight-for-Age Z-Score, WHO Anthropometric Measure of Weight-for-Length Z-Score and 5 more. Started Nov 2020; status: completed.
02
Drugs
CH505TF gp120
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04607408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04607408.